### **Patent Application**

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor:	Wayne V. Vedeckis et al.
Filing Date:	July 8, 2003
Serial Number:	10/
Title:	Human Glucocorticoid Receptor 1A Promoter and Splice Variants
Attorney File:	Vedeckis 97M20-D

Mail Stop Patent Application Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

#### PRELIMINARY AMENDMENT

Dear Sir:

Please amend the application as follows:

# In the Specification:

At page 1, line 11 please insert:

-- This is a divisional of copending application serial number 09/552,619, filed April 18, 2000, now allowed with issue fee paid.--

The abstract has been amended as shown in the attached pages.

# In the Claims:

Please delete claims 5-6 and 8-13.

#### Remarks

The specification has been amended to claim divisional priority from a prior non-provisional application.

The abstract has been amended to comply with 37 C.F.R. § 1.72(b). Changes in the text of the abstract are supported, for example, by the specification, page 6, lines 19-20; page 8, lines 21-23; and in the abstract as originally filed.

Claims 5-6, 8-13 have been canceled. Claims 1-4, 7, and 14-22 remain in the application. Examination of Claims 1-4, 7 and 14-22 are respectfully requested.

Respectfully submitted,

Bonnie I/Davis

Registration No. 41,699

Taylor, Porter, Brooks & Phillips, L.L.P.

P.O. Box 2471

Baton Rouge, Louisiana 70821

(225) 387-3221

July 8, 2003

## **Revised Claim Listing**

- (Original.) A hGR 1Ap/e gene of the human glucocorticoid receptor promoter 1A and exon 1A comprising at least 2056 bases of SEQ ID NO: 1.
- 2. (Original.) A hGR 1Ap/e gene as in Claim 1, wherein the promoter region comprises the region from -1075 to -1 of SEQ ID NO: 1 as numbered in Figure 1.
- 3. (Original.) A hGR 1Ap/e gene as in Claim 1, wherein the exon region comprises the region from +1 to +981 of SEQ ID NO: 1 as numbered in Figure 1.
- 4. (Original.) A human glucocorticoid receptor exon 1A region as in Claim 3, wherein transcription of the exon region results in a mRNA transcript.
  - 5. (Canceled.)
  - 6. (Canceled.)
- 7. (Original.) A mRNA transcript of human glucocorticoid receptor exon 1A region as in claim 4, wherein the transcript results from transcription of the region +1 to +981 of SEQ ID NO: 1 as numbered in Figure 1.

8.
8.

- 9. (Canceled.)
- 10. (Canceled.)
- 11. (Canceled.)
- 12. (Canceled.)
- 13. (Canceled.)
- 14. (Original.) A method to increase the expression of mRNA transcript as in Claim 7 to treat a patient with T-cell acute lymphoblastic leukemia cells, comprising administering to the patient an enhancing amount of an exogenous demethylating agent to reactivate the human glucocorticoid promoter and exon 1A activity.
- 15. (Original.) The method of claim 14, wherein the demethylating agent is 5-azacytidine.

- 16. (Original.) A hGR 1Ap/e promoter-heterologous gene construct comprising all or a portion of SEQ ID NO:1 and a heterologous gene, wherein expression of the heterologous gene of the construct is under transcriptional control of the hGR 1Ap/e promoter.
  - 17. (Original.) The method of claim 16, wherein the heterologous gene codes for a toxin.
- 18. (Original.) A method to kill targeted cells by administering an exogenous dose of glucocorticoid, comprising transforming targeted cells by introducing into said cells the gene construct of claim 17.
- 19. (Original.) A method to convert glucocorticoid-resistant lymphoblasts to glucocorticoid-sensitive lymphoblasts, comprising introducing all or a functional portion of SEQ ID NO: 1 into the hormone-resistant lymphoblasts.
- 20. (Original.) An antisense transgene comprising all or a functional portion of the promoter region of SEQ ID NO: 1 linked to a fragment of the exon region of SEQ ID NO:1 in the antisense orientation.
- 21. (Original.) A method to inhibit hGR1A GR mRNA from being up-regulated in cells, comprising introducing into said cells the antisense transgene of Claim 20.

22. (Original.) A method to prevent neuronal apoptosis caused by excessive glucocorticoid secretion, comprising introducing into said neuronal cells the antisense transgene of Claim 20.

#### **REVISED ABSTRACT**

A new sequence, hGR 1Ap/e, has been isolated from human DNA upstream from the previously known 2.7 kbp human GR promoter region. This new sequence was found to contain a new promoter (the 1A GR promoter) and a new untranslated exon sequence (GR exon 1A) for the human glucocorticoid receptor protein (hGR). The hGR 1Ap/e sequence is approximately 25 kilobase pairs upstream of the hGR coding sequence. Alternative splicing produces three different hGR 1A-containing transcripts, 1A1, 1A2, and 1A3. [GR transcripts containing exons-1A1, 1A2, 1B, and 1C are expressed at various levels in many cancer cells and in the human brain.] Exon 1A3containing GR transcripts appear to be restricted to blood cell cancers and to the human brain. Glucocorticoid hormone treatment caused an up-regulation of exon 1A3-containing GR transcripts in T-lymphoblast cells, and a down-regulation of exon 1A3-containing transcripts in B-lymphoblast cells. This reaction correlates with the known response of the two cells to glucocorticoid hormone treatment, i.e., B-lymphoblast cells are known to be resistant to glucocorticoid hormone treatment and T-lymphoblast cells are known to be sensitive. Thus the presence of exon 1A3-containing transcripts can be used to detect cancerous blood cells that would be sensitive to glucocorticoid hormone treatment. Additionally, an interferon regulatory factor element (IRF-E) that binds IRF-2 was found in the exon 1A sequence. This regulatory factor appears to contribute significantly to basal transcription rate of 1A GR transcripts. The intraexonic location of this sequence was surprising. A glucocorticoid response element (GRE) was also found intraexonically in the exon 1 A sequence. The presence of these two regulatory factors indicates that both interferon and glucocorticoid hormone could be used to increase the level of exon 1A3-containing transcripts in the

cells. There are ~1075 base pairs of hGR 1A promoter sequence, based upon the absence of these sequences in mRNA. There are ~981 bp of exon 1A sequence. The portions of the hGR 1Ap/e sequence that function as a eukaryotic promoter and intraexonic regions that increase promoter activity were identified based on reporter gene assays. The Thus detection of exon 1A3-containing transcripts can be used for the diagnosis of patients with blood cell cancers, including T-cell acute lymphoblastic leukemia (ALL) and other glucocorticoid-responsive cancers, and to identify patients that would benefit from glucocorticoid hormone treatment.